Impel NeuroPharma, a Seattle, WA-based biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs, completed a $67.5m Series D financing.
The round was co-led by KKR and Norwest Venture Partners, with participation from existing investors Vivo Capital, 5AM Ventures and venBio Partners. In conjunction with the financing Dr. Robert Mittendorff, Partner at Norwest, and Ali Satvat, Member at KKR, will join the Impel Board of Directors.
The company intends to use the funds to accelerate its existing clinical development portfolio in CNS disorders.
Led by Jon Congleton, Chief Executive Officer, Impel NeuroPharma is a biotechnology company devoted to creating innovative therapies for central nervous system (CNS) diseases.
The company’s products utilize its novel, nasal drug-delivery Precision Olfactory Delivery, or POD™, device technology to deliver liquid or dry powder forms of drug to the upper nasal cavity in a consistent and predictable manner.
Impel is currently investigating three programs leveraging its novel Precision Olfactory Delivery, or POD®, device technology:
– INP104 in a Phase 3 trial for the treatment of acute migraine headache,
– INP103 in a Phase 2 trial for the reversal of OFF episodes in Parkinson’s disease, and
– INP105 in a Phase 1 trial for the treatment of acute agitation in bipolar I and schizophrenia disorders.